EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical laboratory characteristics and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2 , MPL , or CALR

Zhanlong Wang iD, Xin Tian iD, Jinyu Ma iD, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, Enbin Liu, Yani Lin und 3 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zhanlong Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Laboratories, Clinical, Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Key Research and Development Program of China, the National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2 , MPL , or CALR .

Methods

We collected a total of 359 Ph ‐negative MPN patients with classical mutations in driver genes JAK2 , MPL , or CALR , and divided them into two groups based on whether they had additional atypical variants of driver genes JAK2 , MPL , or CALR : 304 patients without atypical variants of driver genes and 55 patients with atypical variants of driver genes. We analyzed the relevant characteristics of these patients.

Results

This study included 359 patients with Ph ‐negative MPNs with JAK2 , MPL , or CALR classical mutations and found that 55 (15%) patients had atypical variants of JAK2 , MPL , or CALR . Among them, 28 cases (51%) were male, and 27 (49%) were female, with a median age of 64 years (range, 21–83). The age of ET patients with atypical variants was higher than that of ET patients without atypical variants [70 (28–80) vs. 61 (19–82), p = 0.03]. The incidence of classical MPL mutations in ET patients with atypical variants was higher than in ET patients without atypical variants [13.3% (2/15) vs. 0% (0/95), p = 0.02]. The number of gene mutations in patients with atypical variants of driver genes PV, ET, and Overt‐PMF is more than in patients without atypical variants of PV, ET, and Overt‐PMF [PV: 3 (2–6) vs. 2 (1–7), p < 0.001; ET: 4 (2–8) vs. 2 (1–7), p < 0.05; Overt‐PMF: 5 (2–9) vs. 3 (1–8), p < 0.001]. The incidence of SH2B3 and ASXL1 mutations were higher in MPN patients with atypical variants than in those without atypical variants ( SH2B3 : 16% vs. 6%, p < 0.01; ASXL1 : 24% vs. 13%, p < 0.05).

Conclusion

These data indicate that classical mutations of JAK2 , MPL , and CALR may not be completely mutually exclusive with atypical variants of JAK2 , MPL , and CALR . In this study, 30 different atypical variants of JAK2 , MPL , and CALR were identified, JAK2 G127D being the most common (42%, 23/55). Interestingly, JAK2 G127D only co‐occurred with JAK2 V617F mutation. The incidence of atypical variants of JAK2 in Ph ‐negative MPNs was much higher than that of the atypical variants of MPL and CALR . The significance of these atypical variants will be further studied in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laboratories, ClinicalTranscription FactorsHumansFemaleMaleYoung AdultAdultMiddle AgedAgedAged, 80 and overMutationReceptors, ThrombopoietinJanus Kinase 2

Stichwörter der Autor:innen

atypical variantclassical mutationco‐existencedriver genesmyeloproliferative neoplasms

Substanzen

Transcription FactorsMPL protein, humanReceptors, ThrombopoietinJAK2 protein, humanJanus Kinase 2

Autor:innen und Institutionen

  • Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Sino-US Diagnostics Lab, Tianjin Enterprise Key Laboratory of AI-aided Hematopathology Diagnosis, Tianjin, China.
  • State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Department of Pathology and Lab Medicine, Shandong Cancer Hospital, Jinan, China.

ORCID-Profile: Zhanlong Wang, Xin Tian, Jinyu Ma, Weiping Yuan, Jie Bai

Förderung

  • The National Key Research and Development Program of China
  • the National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • the Municipal Education Commission Scientific Research Plan Project of Tianjin

Zitieren

APA

Wang, Z., Tian, X., Ma, J., Zhang, Y., Ta, W., Duan, Y., Li, F., Zhang, H., Chen, L., Yang, S., Liu, E., Lin, Y., Yuan, W., Ru, K., & Bai, J. (2024). Clinical laboratory characteristics and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2 , MPL , or CALR. Cancer Medicine. https://doi.org/10.1002/cam4.7123

Vancouver

Wang Z, Tian X, Ma J, Zhang Y, Ta W, Duan Y, et al. Clinical laboratory characteristics and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2 , MPL , or CALR. Cancer Medicine. 2024. doi:10.1002/cam4.7123

BibTeX
@article{Wang2024,
  author = {Wang, Zhanlong and Tian, Xin and Ma, Jinyu and Zhang, Yuhui and Ta, Wenru and Duan, Yifan and Li, Fengli and Zhang, Hong and Chen, Long and Yang, Shaobin and Liu, Enbin and Lin, Yani and Yuan, Weiping and Ru, Kun and Bai, Jie},
  title = {Clinical laboratory characteristics and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2 , MPL , or CALR},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7123}
}
Kostenlos starten →